Aesculap sees revival in Germany
This article was originally published in Clinica
Aesculap (Germany) has reported a 6.5% rise in turnover in the first six months of fiscal 1995. Sales totalled DM 272.8 million ($195 million) in the period, led by high growth in the service sector and a revival in the German market.
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.